Theriva Biologics
TOVX
39 hedge funds and large institutions have $70.6M invested in Theriva Biologics in 2015 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 9 closing their positions.
36% more capital invested
Capital invested by funds: $51.9M → $70.6M (+$18.6M)
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
3% more funds holding
Funds holding: 38 → 39 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair & Company
Chicago,
Illinois
|
+$2.49M |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$482K |
| 3 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
+$381K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$241K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$201K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIC
Carnegie Investment Counsel
Pepper Pike,
Ohio
|
-$756K |
| 2 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$321K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$238K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$213K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
-$161K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$11K | -1 | Closed |
|
52
UBS Group
Zurich,
Switzerland
| – | -$14K | -1 | Closed |
|
53
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$8 | – | – |
|
|
NFG
54
Next Financial Group
Houston,
Texas
| – | -$8K | – | – |
|
TOVX Hedge Fund Activity: Q2 2015 in Review
39 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q2 2015, worth a combined $70.6M — up 36% from $51.9M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new TOVX positions and 9 closed out — a net gain of 1 holder — while 6 added to existing stakes and 6 trimmed.
The largest buyer was William Blair & Company, opening a new position worth an estimated $2.49M. The largest seller was Carnegie Investment Counsel, exiting entirely with an estimated $756K sold.
- 39 institutional investors held Theriva Biologics (TOVX) as of Q2 2015, up from 38 in Q1 2015.
- Funds reported $70.6M of Theriva Biologics stock for Q2 2015, up 36% quarter-over-quarter.
- 10 funds opened new Theriva Biologics positions in Q2 2015 and 9 closed out, a net change of +1 holder.
- The largest Theriva Biologics buyer in Q2 2015 was William Blair & Company, an estimated $2.49M added.
- The largest Theriva Biologics seller in Q2 2015 was Carnegie Investment Counsel, an estimated $756K sold.
Based on aggregated 13F filings for Q2 2015.